[Efficacy and tolerability of choline alphoscerate (cereton) in patients with Parkinson's disease with cognitive disorders].

An open 10-day study of treatment effect of cereton in comparison to piracetam has been conducted. Cereton was used in 40 patients (main group) in dosage 1000 mg, piracetam - in 20 patients (control group) in dosage 2000 mg. Both drugs were used intravenous in drops in 200 ml of physiologic saline along with antiparkinsonian medications. Patient's state was assessed with a battery of psychometric scales and neuropsychological tests as well as with instruments for measuring intensity of parkinsonian symptoms, side-effects and quality of life. Marked and moderate improvement of cognitive functions was found in patients of the main group compared to the control one (40% and 25%, respectively, p<0,05). Deterioration of cognitive functions was seen less often in the main group than in the control group (5% and 15%, respectively, p<0,05). Cereton was well-tolerated by patients. Side effects (brief and short-term) were found only in 6 (15%) patients.

[Efficacy of acatinol memantine in mild cognitive disorder].

An open 6 month clinical trial of efficacy of acatinol has been carried out in patients with mild cognitive disorder (MCD). Forty patients received acatinol and 20 patients of comparison group were treated with piracetam. Mean age of patients was 67,7+/-7,2 years. Patient's state was assessed with a battery of scales, questionnaires and neuropsychological tests. Acatinol was prescribed in dosage 10 mg daily and piracetam in dosage 1200 mg daily at baseline, after 3 and 6 months of treatment. Thirty-eight (95%) of patients treated with acatinol and 18 (90%) of patients treated with piracetam have completed the treatment. In the acatinol group, worsening was seen in 5% of patients, no changes - in 20%, moderate improvement - in 35%, marked improvement - in 25%, substantial improvement - in 15%. Portion of patients with worsening or absence of changes was significantly lower and that with marked and substantial improvement was higher in the acatinol group compared to the piracetam group. The global assessment of cognitive functions on the MMSE scale was significantly increased to the end of 3rd month in both groups. However this improvement was maintained to the end of 6th month only in patients treated with acatinol. In the latter group, the positive changes of depressive symptoms, subjective symptoms and quality of life were shown. The positive dynamics was more pronounced in patients with dysregulation type of MCD compared to patients with amnesic type. The authors suggest a term <>. For this type of MCD the use of acatinol may be most necessary.